Aspen Pharmacare Holdings Limited (JSE:APN)
South Africa
· Delayed Price · Currency is ZAR · Price in ZAc | Market Cap | 61.84B |
| Revenue (ttm) | 42.59B |
| Net Income (ttm) | -2.00B |
| Shares Out | 444.02M |
| EPS (ttm) | -4.50 |
| PE Ratio | n/a |
| Forward PE | 15.41 |
| Dividend | 2.11 (1.51%) |
| Ex-Dividend Date | Oct 1, 2025 |
| Volume | 1,427,383 |
| Average Volume | 1,066,479 |
| Open | 13,201 |
| Previous Close | 13,928 |
| Day's Range | 13,201 - 14,200 |
| 52-Week Range | 9,070 - 14,458 |
| Beta | 0.35 |
| RSI | 63.63 |
| Earnings Date | Sep 2, 2026 |
About Aspen Pharmacare Holdings
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counte... [Read more]
Financial Performance
Financial StatementsNews
Aspen Pharmacare Holdings Earnings Call Transcript: H1 2026
First half 2026 saw commercial pharma growth offset by manufacturing declines, with strong GLP-1 performance and improved free cash flow. The APAC divestment will eliminate debt and enhance balance sheet flexibility, while double-digit EBITDA and HEPS growth are forecasted for the full year.
Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter
Aspen Pharmacare's unbranded version of Novo Nordisk's popular diabetes drug Ozempic could be registered in Canada in the second or third quarter of this year, the South African pharmacueticals g...
Aspen Pharmacare Holdings Transcript: Status update
Divestment of the APAC business for ZAR 26.5 billion will significantly reduce debt and enhance balance sheet flexibility, with proceeds used to drive organic growth in pharma and manufacturing. GLP-1s and contract manufacturing are key future growth drivers.
Aspen Pharmacare Holdings Earnings Call Transcript: H2 2025
Despite macroeconomic turbulence and a major contract loss, commercial pharma delivered strong growth, especially in Africa and Latin America. EBITDA and earnings were impacted by FX and tax changes, but cash conversion was robust. Outlook is positive, with focus on cost control, manufacturing turnaround, and GLP-1 opportunities.
Aspen Pharmacare Holdings Earnings Call Transcript: H1 2025
Strong H1 2025 results with double-digit CER growth in revenue and EBITDA, driven by robust commercial pharma and manufacturing performance. Strategic progress in GLP-1, insulin, and vaccine manufacturing positions the business for sustained growth, despite currency and tax headwinds.
Aspen Pharmacare Holdings Earnings Call Transcript: H2 2024
Revenue grew 10% year-over-year, driven by manufacturing and commercial pharma, with EBITDA and HEPS up 17% in H2. Strategic focus on GLP-1s and sterile manufacturing positions for strong future growth, while risks from regulatory timelines and pricing remain.
Aspen Pharmacare Holdings Earnings Call Transcript: H1 2024
South Africa's Aspen Pharmacare to buy Sandoz's China business
Aspen Pharmacare will buy the Chinese business of Swiss group Sandoz , including commercialisation rights and intellectual property for some established products and those in the pipeline, for up to 9...